NCT05195710 is a Phase 1 clinical trial of Yttrium-90 (Y-90) resin microspheres in Metastases, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05195710?

NCT05195710 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05195710?

Interventions in NCT05195710: Yttrium-90 (Y-90) resin microspheres.

What condition does NCT05195710 study?

NCT05195710 studies Metastases.

Is NCT05195710 still recruiting?

NCT05195710 is currently recruiting now. Last updated 10 November 2025.

Last reviewed 2025-11-10 · How we verify

NCT05195710

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Recruiting now Phase 1 Last updated 10 November 2025

What this trial tests

Phase 1 trial testing Yttrium-90 (Y-90) resin microspheres in Metastases in 50 participants. Currently enrolling.

Timeline

16 November 2022

Primary endpoint
31 March 2026

31 March 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	16 November 2022
Primary completion	31 March 2026
Estimated completion	31 March 2026
Sites	1 location across United States

Drugs / interventions tested

Yttrium-90 (Y-90) resin microspheres — full drug profile →

Conditions studied

Metastases — all drugs for Metastases →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Overview of Ongoing Clinical Trials on Radioembolization.
Fabritius MP, Ricke J. · · 2022 · cited 7× · PMID 36184696 · DOI 10.1007/s00270-022-03270-4

Verify or expand the search:

Other trials of Yttrium-90 (Y-90) resin microspheres

Trials testing the same drug.

NCT06712017 — Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China · enrolling by invitation

Other recruiting trials for Metastases

Currently open trials in the same condition.

NCT06713161 — Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Sta · recruiting
NCT06356779 — Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease · NA · recruiting
NCT04987086 — 68Ga-PSMA PET in the Renal Cell Carcinoma · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05195710 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 10 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05195710.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing